Novartis receives FDA approval for Rhapsido® , the only oral, targeted BTKi treatment for chronic spontaneous urticaria
55 North Mining Appoints Wayne Parsons as Executive Chair; Strengthens Leadership as the Company Advances the Last Hope Gold Project
